TY - T1的初始后很长一段路要走experience with balloon pulmonary angioplasty JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00718-2017 VL - 49 IS - 6 SP - 1700718 AU - Matsubara, Hiromi AU - Ogawa, Aiko Y1 - 2017/06/01 UR - //www.qdcxjkg.com/content/49/6/1700718.abstract N2 - To date, the standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH) has been surgical pulmonary endarterectomy (PEA) followed by life-time anticoagulation therapy [1]. However, excellent results with PEA have been limited to select centres with experience and expertise; many patients who are possible candidates for PEA at expert centres would be considered ineligible in many countries [2]. Medical treatment has shown little or no improvement in haemodynamic parameters in patients with CTEPH who are ineligible for PEA [3, 4]. Thus, despite partial success of balloon pulmonary angioplasty (BPA) in the USA [5], attempts to treat patients with CTEPH by BPA have increased in several countries where PEA is not widely performed [6–8]. Before starting a BPA programme, two main problems in the initial report [5] need to be resolved: its low efficacy and high incidence of complication.To improve efficacy and safety of balloon pulmonary angioplasty, accumulation of experience and knowledge is needed http://ow.ly/lVSj30bFFNh ER -